Enzon Pharmaceuticals, Inc.

OTCPK:ENZN Stock Report

Market Cap: US$7.5m

Enzon Pharmaceuticals Valuation

Is ENZN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ENZN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$0.31
Fair Value
67.7% undervalued intrinsic discount
0
Number of Analysts

Below Fair Value: ENZN ($0.1) is trading below our estimate of fair value ($0.31)

Significantly Below Fair Value: ENZN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ENZN?

Key metric: As ENZN barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ENZN. This is calculated by dividing ENZN's market cap by their current book value.
What is ENZN's PB Ratio?
PB Ratio2.5x
BookUS$3.01m
Market CapUS$7.50m

Price to Book Ratio vs Peers

How does ENZN's PB Ratio compare to its peers?

The above table shows the PB ratio for ENZN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.1x
TSBX Turnstone Biologics
0.2x58.4%US$8.6m
LPTX Leap Therapeutics
0.3x3.3%US$15.3m
APVO Aptevo Therapeutics
0.7x37.6%US$3.5m
GLYC GlycoMimetics
3.2xn/aUS$17.0m
ENZN Enzon Pharmaceuticals
2.5xn/aUS$7.5m

Price-To-Book vs Peers: ENZN is expensive based on its Price-To-Book Ratio (2.5x) compared to the peer average (1.1x).

Price to Book Ratio vs Industry

How does ENZN's PB Ratio compare vs other companies in the US Biotechs Industry?

53 CompaniesPrice / BookEstimated GrowthMarket Cap
NKTX Nkarta
0.3x-9.5%US$117.14m
MGX Metagenomi
0.3x-18.1%US$72.60m
IMAB I-Mab
0.3x-8.0%US$68.40m
IPSC Century Therapeutics
0.3x-17.0%US$50.70m
ENZN 2.5xIndustry Avg. 1.5xNo. of Companies66PB01.22.43.64.86+
53 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ENZN is expensive based on its Price-To-Book Ratio (2.5x) compared to the US Biotechs industry average (1.5x).

Price to Book Ratio vs Fair Ratio

What is ENZN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ENZN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ENZN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/16 04:14
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Enzon Pharmaceuticals, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert HazlettBMO Capital Markets U.S. (Historical)
Pamela BassettCantor Fitzgerald & Co.
James MolloyCaris & Company